Ashli Morgan, Krishna Mohan Sepuru1, Wei Feng, Krishna Rajarathnam1, Xu Wang. 1. ‡Department of Biochemistry and Molecular Biology, Sealy Center for Structural Biology and Molecular Biophysics, University of Texas Medical Branch, Galveston, Texas 77555, United States.
Abstract
Decorin binding protein A (DBPA) is a glycosaminoglycan (GAG)-binding adhesin found on the surface of the bacterium Borrelia burgdorferi (B. burgdorferi), the causative agent of Lyme disease. DBPA facilitates bacterial adherence to extracellular matrices of human tissues and is crucial during the early stage of the infection process. Interestingly, DBPA from different strains (B31, N40, and PBr) show significant differences in GAG affinities, but the structural basis for the differences is not clear. In this study, we show that GAG affinity of N40 DBPA is modulated in part by flexible segments that control access to the GAG binding site, such that shortening of the linker leads to higher GAG affinity when analyzed using ELISA, gel mobility shift assay, solution NMR, and isothermal titration calorimetry. Our observation that GAG affinity differences among different B. burgdorferi strains can be attributed to a flexible linker domain regulating access to the GAG-binding domain is novel. It also provides a rare example of how neutral amino acids and dynamic segments in GAG binding proteins can have a large influence on GAG affinity and provides insights into why the number of basic amino acids in the GAG-binding site may not be the only factor determining GAG affinity of proteins.
Decorin binding protein A (DBPA) is a glycosaminoglycan (GAG)-binding adhesin found on the surface of the bacterium Borrelia burgdorferi (B. burgdorferi), the causative agent of Lyme disease. DBPA facilitates bacterial adherence to extracellular matrices of human tissues and is crucial during the early stage of the infection process. Interestingly, DBPA from different strains (B31, N40, and PBr) show significant differences in GAG affinities, but the structural basis for the differences is not clear. In this study, we show that GAG affinity of N40DBPA is modulated in part by flexible segments that control access to the GAG binding site, such that shortening of the linker leads to higher GAG affinity when analyzed using ELISA, gel mobility shift assay, solution NMR, and isothermal titration calorimetry. Our observation that GAG affinity differences among different B. burgdorferi strains can be attributed to a flexible linker domain regulating access to the GAG-binding domain is novel. It also provides a rare example of how neutral amino acids and dynamic segments in GAG binding proteins can have a large influence on GAG affinity and provides insights into why the number of basic amino acids in the GAG-binding site may not be the only factor determining GAG affinity of proteins.
Decorin-binding
protein (DBP)
is a surface lipoprotein found on the bacterium Borrelia
burgdorferi (B. burgdorferi), the causative agent of Lyme disease. DBP adheres to the connective
tissue proteoglycan decorin, which allows the bacterium to be retained
in the extracellular space of the host tissue.[1,2] Studies
have shown DBPs attach to decorin mainly by binding glycosaminoglycans
(GAGs) on decorin.[1,3] GAGs are linear, sulfated polysaccharides
ubiquitous to all mammals. Although GAG polysaccharides contain only
two types of monosaccharides, they are among the most complex biomolecules
because of the semirandom modifications of these monosaccharides through
epimerization and sulfation.[4] DBPs are
known to bind several GAGs. Besides dermatan sulfate (DS), the type
of GAG most commonly found in decorin, DBPs also bind heparin and
heparan sulfate (HS).[5] Although all three
GAGs have high levels of iduronic acid, DS alone contains N-acetylgalactosamine
(GalNAc) while heparin/HS contain glucosamine (Figure A). DBPA’s ability to bind different
GAG types may be a factor in determining its tissue tropism. In fact,
studies have shown DBP’s affinity for various GAG types is
correlated with its adherence to different host organs.[6,7]
Figure 1
(A)
Chemical structures of representative disaccharide units found
in DS and heparin. (B) Ribbon representations of B31, N40, and PBr
DBPA structures. Basic amino acids found in the GAG-binding pocket
are labeled. The extra cluster of basic amino acids found in the linker
of B31 DBPA is labeled in red.
(A)
Chemical structures of representative disaccharide units found
in DS and heparin. (B) Ribbon representations of B31, N40, and PBrDBPA structures. Basic amino acids found in the GAG-binding pocket
are labeled. The extra cluster of basic amino acids found in the linker
of B31 DBPA is labeled in red.Two homologous forms of DBP, DBPA and DBPB, exist in the B. burgdorferi genome. The two homologues share about 40%
sequence identity and both are crucial to the early stage infection
process.[8,9] In particular, deletion of DBPA/B genes
attenuates virulence by 3 to 4 orders of magnitude. Interestingly,
whereas the sequence of DBPB is highly conserved, the sequence of
DBPA is less conserved among different strains. Significance of these
sequence variations lies in their effect on differences in the clinical
manifestation of Lyme disease. Recent studies by Leong and co-workers
showed that DBPAs from different strains have very different affinities
for GAGs, and DBPA sequence alone was sufficient in determining tissue
tropism of the bacterium.[10,11] In particular, they
found that transfecting bacterial strains naturally devoid of DBPA
with PBrDBPA, which binds DS with a KD 0.21 μM, led to bacterial colonization in the heart, whereas
expression of N40DBPA, which binds DS with a KD 3.10 μM, resulted in localization to the knee. These
results show that GAG affinity and specificity of DBPA dictate bacterium
localization, and therefore understanding the molecular basis underlying
DBPA–GAG interactions may lead to advanced prediction of the
clinical manifestation of the disease.So far, structures of
DBPA from three different strains of Borrelia spirochetes have been determined.[12,13] Despite the
sequence differences, their structures are very similar.
All structures contain five helices and two flexible segments. The
helical bundle is stabilized by a considerable hydrophobic core, and
a GAG-binding site can be found on its surface (Figure B). This GAG-binding site includes at least
four basic residues from helix-1, -2, and -5, and their assembly produces
a sizable basic pocket. Mutagenesis studies showed that this basic
pocket is critical to DBPA’s affinity for GAGs.[12,14,15] Intriguingly, the basic pocket
is proximal to a long unstructured linker between helix-1 and -2 as
well as an unstructured C-terminus. NMR dynamics studies show that
both segments are highly flexible.[16] Equivalent
segments in the crystal structure of DBPA from strain 297 also showed
high B factors,[12] indicating that these
residues are dynamic in most strains of DBPA. Moreover, both segments
remained flexible even in the presence of GAGs.[13,16]Despite their flexibilities, both unstructured segments seem
to
play a role in GAG binding. A previous structural study of DBPA from
strain B31 showed residues in these two segments experienced higher
chemical shift perturbations upon binding heparin than residues in
the basic pocket.[15] This indicates the
flexible segments, far from being innocuous bystanders, may play a
significant role in modulating GAG binding.In principle, potential
roles of the linker could be gleaned by
comparing DBPA structures of B31 and N40 strains. Despite ∼80%
sequence identity and identical basic amino acid arrangement in the
binding pocket (Figure B), the two DBPAs have significantly different affinities for GAGs.[10,11] Mutagenesis study showed additional basic amino acids in the linker
of B31 DBPA (K64, K66, and K67) contribute to the higher GAG affinities,
indicating the amino acid composition of the linker is a critical
factor in determining GAG affinities. Interestingly, DBPA from the
PBr strain lacks basic amino acids in its linker, and yet this version
of DBPA has the highest GAG affinity of all strains.[10,11] Comparative structural analysis showed that PBrDBPA has a structured
linker between helix-1 and -2, leading to the retraction of the linker
(Figure B). These
observations led us to propose that the linker serves not as a facilitator
of GAG binding, but actually impedes interactions by blocking access
to the basic pocket.In this study, we report the experimental
evidence to support this
hypothesis. Specifically, we show that N40DBPA mutants with shortened
linkers have significantly higher GAG affinities, consistent with
the theory that accessibility of the GAG-binding pocket can be improved
with the removal of the linker. This mechanism explains much of the
known relationship between structural differences and GAG affinities
of DBPAs from various Borrelia genospecies.
To the best of our knowledge, this is the first report of GAG affinities
being modulated by dynamic segments outside the binding site residues.
It also shows that the number of basic amino acids in a GAG-binding
site may not be the only determining factor of proteins’ GAG
affinities.
Experimental Procedures
Expression and Purification of N40 DBPA Variants
Open
reading frame (ORF) of N40DBPA was synthesized by GenScript Inc.
(Piscataway, NJ). The ORF for the wild-type (WT) mature DBPA strain
N40 (residues 29–194) was cloned into the pHUE vector, resulting
in a fusion protein of His-tagged ubiquitin at the N-terminus.[17] The mutants for N40DBPA were created using
site-directed mutagenesis from the WT sequence for DBPA (only N40Δ62–71,neu mutant used N40Δ62–71 sequence). The forward primers for the DBPA linker deletion mutants
are as follows: N40Δ62–66, 5′-ATCAAAAAGGATGCGGCCGACAACAATGTCACCGATTCCGAAACGGGCAGTAAAGTG-3′;
N40Δ62–71, 5′-ATCAAAAAGGATGCGGCCGACAACAATGTCGGCAGTAAAGTGTCCGAAAACTCATTT-3′;
and N40Δ62–74, 5′-ATCAAAAAGGATGCGGCCGACAACAATGTCGTGAAAGAAGGCTCATTTATCCTGGAAGCA-3′.
The forward primers for the neutral linker mutants are as follows:
D68S/E70S, 5′-GCAGCTTTCACCAGCTCCAGCACGGGCAGTAAAGTGTCCG-3′;
K74S (the mutations D68S/E70S/K74S are for the mutant N40neutral), 5′-GCTCCAGCACGGGCAGTAGCGTGTCCGAAAACTC-3′;
and N40Δ62–71 K74S (N40Δ62–71,neu), 5′-GCCGACAACAATGTCGGCAGTAGCGTGTCCGAAAACTC-3′.
The forward primers for the DBPA C-terminal mutant (C176,191S) to
remove the disulfide bond are as follows: C176S, 5′-GTCCACACGAAAAACTACAGCGCACTGGAAAAGAAGAAAAACCCG-3′
and C191S, 5′-CCGAATTTCACCGACGAAAAGAGCAAAAACAATTAAAAGCTTAGATCCGGC-3′.
Sequencing was used to confirm the correct deletion mutations.Each plasmid was transformed into E. coli BL21(DE3); then, the bacteria were grown at 37 °C to an OD600 of 0.5. Isotopically labeled protein was grown in M9 medium
supplemented with 15NH4Cl and glucose. The bacteria
were induced with 0.5 mM IPTG and incubated overnight at 30 °C.
To lyse the cells after harvesting, the resuspended pellet was incubated
with 1 mg/mL lysozyme and sonicated. The fusion protein was extracted
from the cleared supernatant using Ni affinity chromatography with
a 5 mL HisTrap column (GE Life Sciences) and was eluted using an imidazole
gradient of 25–300 mM at a flow rate of 3 mL/min. The collected
fusion protein was exchanged into 25 mM Tris (pH 8.0), 100 mM NaCl,
and was digested with USP2 as well as 1 mM DTT overnight at room temperature
(RT). The cleaved DBPA was separated using a 5 mL HisTrap column and
was eluted in the flowthrough that was then collected, concentrated,
and exchanged into 50 mM phosphate pH 6.5, 150 mM NaCl.
ELISA Analysis
of Heparin and DS Binding to N40 DBPA Variants
Intact heparin
and DS were biotinylated and quantified with the
Biotinylation Quantitation kit (Pierce) according to the manufacturer’s
instructions. Neutravidin-coated microplates (G-Biosciences) were
coated with 100 μL of PBS containing 20 μg/mL of biotinylated
heparin or DS and incubated with 2 μg of His-tagged WT N40DBPA
and N40DBPA mutants in 100 μL PBS for 1 h. The bound protein
was quantified using 1:2000 Anti-His HRP (Qiagen) and developed with
tetramethylbenzidine (TMB) substrate solution. 100 μL of 0.1
M sulfuric acid was added to each well to stop the reaction after
2 min (heparin) or after 12 min (DS), inducing a color change that
was read at 450 nm. Each ELISA assay was performed at least twice,
and data from four replicates of every sample were averaged to obtain
the mean and standard deviation.
Production of Heparin and
DS Fragments
Commercially
available heparin and DS were digested with either heparinase I (heparin)
or chondroitinase ABC (DS) until 30% of available sites are cleaved.
Digests were monitored by measuring absorbance at 232 nm to determine
extent of digests. The partially depolymerized GAGs were then separated
with a size exclusion chromatography column (Bio-Rad Biogel P10) to
obtain homogeneous size-defined fragments.
Gel Mobility Shift Assays
for N40 DBPA Variants
Heparindp8 (degree of polymerization 8, or octasaccharide) and DS dp8 fragments
were fluorescently labeled with 0.1 M 2-aminoacridone (2-AMAC) as
described by Lyon et al.[18] The assay was
performed by incubating 2 μg of the 2-AMAC labeled heparindp8
or DS dp8 with either 0.5 (heparin) or 1 (DS) mol equiv of DBPA in
50 mM sodium phosphate pH 6.5, 150 mM NaCl for a total volume of 12.5
μL. The reaction mixtures were incubated at RT for 30 min, and
run in a 2% agarose gel at 120 V for 15–20 min. A UV panel
was used to visualize the shifts.[19] Quantification
was carried out by comparing brightness-weighted pixel counts of the
free bands in the presence and absence of the protein.
Titrations
of WT and Mutant N40 with Heparin dp8
1H–15N HSQC spectra were collected on a Bruker
Ultra-Shield 600 MHz spectrometer. The NMR titration data were used
to estimate KD values for the interaction
between heparindp8 and the DBPAN40 variants at pH 6.5. A total of
18 mol equiv of heparindp8 were added in aliquots of either 2 or
4 mol equiv to 400 μL of 150 μM protein. The chemical
shift changes noted in each 1H–15N HSQC
spectrum were normalized into one chemical shift value using the equation,
δH = [ΔδH2 + 1.7ΔδN)2]1/2, where δH and δN represent the chemical shifts for 1H and 15N in hertz, respectively.[20] The binding
curves were fitted using the one-to-one binding model contained in
the software xcrvfit (http://www.bionmr.ualberta.ca/bds/software/xcrvfit/) to extract the KD values.
Isothermal
Titration Calorimetry (ITC)
The binding
affinities of DBPAN40 variants were characterized by measuring the
heat changes on titrating dp10 heparin into the DBPA solution using
a Microcal VP titration Calorimeter. Protein and GAG solutions were
dissolved in 50 mM phosphate 150 mM NaCl (pH 6.5), centrifuged, and
degassed under vacuum before use. Titrations were performed by injecting
2 × 2 μL and 6 × 46 μL aliquots of GAG into
DBPA solution at 25 °C. Data were analyzed using Origin software
supplied by Microcal.
Results
To probe the role of the
linker in modulating GAG affinity of DBPA,
we constructed several mutants containing truncated linkers. We used
WT N40DBPA as our model because, unlike B31 and PBrDBPA, its linker
is not known to contain elements that enhance GAG binding. Chemical
shift perturbation analysis and paramagnetic perturbation using TEMPO-labeled
heparin dp6 ligands both showed that the linker of N40DBPA is minimally
perturbed by heparin,[13] indicating its
interactions with GAG are most likely minimal. This property of N40DBPA allows us to evaluate objectively the impact of the linker length
on GAG affinity without the complication of removing additional GAG-binding
residues in the process.Figure shows the
mutants that were constructed for this study. Specifically, we prepared
three N40DBPA mutants with 5 (residues 62 to 66), 10 (residues 62
to 71), and 13 (residues 62 to 71) residues removed from the linker.
These are designated as N40Δ62–66, N40Δ62–71, and N40Δ62–74,
respectively. Residues were chosen after the impact of linker shortening
on nearby secondary structures was modeled using the program modeler[21] to ensure the integrity of the helices is preserved.
The NMR studies of the mutant N40Δ62–71 also
showed that the integrity of helix-1 and helix-2 flanking the linker
was not compromised. In particular, sequential HN-HN NOESY crosspeaks
and backbone dihedral angles predicted from Cα and Cβ
chemical shifts were consistent with the retention of the helical
structure (Table S1). Besides the linker
truncation mutants, we also engineered mutants without charged amino
acids in the linker and a mutant missing the disulfide bond connecting
the flexible C-terminal linker and helix 5. This disulfide bond tethers
the flexible C-terminus close to the core domain and the basic pocket.
However, the disulfide bond is missing in a number of DBPA sequences,
including PBrDBPA. The Cys mutant (C176S/C191S) of N40DBPA will
allow us to evaluate whether the disulfide bond has any functional
role in DBPA’s GAG-binding activity. There are also a number
of charged amino acids in the linker of N40DBPA (D68, E70, and K74).
Removal of these amino acids may potentially influence DBPA–GAG
interactions. To gauge their contributions to GAG binding, we also
created a mutant having a linker of normal length, but with the three
charged amino acids mutated to Ser (N40neutral), and another version
of the N40Δ62–71 mutant also containing a
neutral linker (N40Δ62–71,neu).
Figure 2
Mutants of
N40 DBPA considered in this study. Sequences of helical
regions of WT N40 DBPA are highlighted in black. The mutations made
in this study are indicated as follows: the three linker deletion
mutations are underlined, the neutral linker mutations are shaded
gray, and the disulfide bond mutation is notated with an asterisk
(*). The linker deletion mutants are as follows: N40Δ62–66, N40Δ62–71, and N40Δ62–74. The neutral linker mutants include N40neutral and N40Δ62–71,neu. The C-terminal disulfide bond was
removed in the mutant C176S/C191S.
Mutants of
N40DBPA considered in this study. Sequences of helical
regions of WT N40DBPA are highlighted in black. The mutations made
in this study are indicated as follows: the three linker deletion
mutations are underlined, the neutral linker mutations are shaded
gray, and the disulfide bond mutation is notated with an asterisk
(*). The linker deletion mutants are as follows: N40Δ62–66, N40Δ62–71, and N40Δ62–74. The neutral linker mutants include N40neutral and N40Δ62–71,neu. The C-terminal disulfide bond was
removed in the mutant C176S/C191S.We first tested the mutants’ affinities for intact
GAGs
with ELISA assays that use immobilized heparin and DS as probes. In
the case of immobilized heparin, mutants with shortened linkers showed
a dramatic increase in binding affinity compared to the WT while C176S/C191S
mutant showed a small decrease in affinity (Figure ). We also performed ELISA using immobilized
DS, the major GAG type found on decorin, as the probe. In agreement
with results of the heparin ELISA, significant improvements in DS
binding affinity can be seen for all linker truncation mutants (Figure ), but the enhancements
were smaller than that of heparin. These results indicate GAG affinity
enhancements stemming from linker shortening may be dependent on GAG
type, and this is potentially a factor in determining the preference
of DBPA for tissue type. Once again, the C176S/C191S mutant showed
a small but statistically significant (p < 0.01)
decrease in DS affinity. We also carried out ELISA on mutants with
neutral linkers to measure whether the enhancement in GAG affinity
is the result of shortening the linker or the elimination of the charged
amino acids. Figure S1 shows the result
of these assays. Specifically, we saw that the mutant with normal
linker length and no charged amino acids in the linker has about the
same binding affinity for GAGs as WT N40DBPA, indicating the net
effect of the charged amino acids on GAGs is minimal. Shortening the
linker resulted in substantial increase in both heparin and DS affinities.
Specifically, N40Δ62–71,neu’s affinity
of heparin increased ∼2.5-fold while its DS affinity doubled.
These are comparable to increases seen in N40Δ62–71.
Figure 3
Effect of mutations in N40 DBPA on GAG-binding as determined by
ELISA. Shortening the linker increased N40 DBPA’s affinity
for GAGs while removal of the C-terminal disulfide bond reduced the
affinity. Student’s t test comparing WT N40
DBPA with each mutant indicates the change in GAG-binding affinity
is statistically significant (p < 0.0001 for both
heparin and DS).
Effect of mutations in N40DBPA on GAG-binding as determined by
ELISA. Shortening the linker increased N40DBPA’s affinity
for GAGs while removal of the C-terminal disulfide bond reduced the
affinity. Student’s t test comparing WT N40DBPA with each mutant indicates the change in GAG-binding affinity
is statistically significant (p < 0.0001 for both
heparin and DS).To obtain a more quantitative
insight, we also probed the binding
interactions using size-defined heparin and DS oligosaccharides. First,
the qualitative affinities of the mutants for heparindp8 (degree
of polymerization 8, or octasaccharides) and DS dp8 were carried out
using gel mobility shift assay (GMSA). The GMSA measures the extent
to which a protein is capable of impeding the electrophoretic migration
of fluorescently labeled GAG ligands. The results showed that the
linker truncated N40DBPA mutants have significantly higher affinity
for heparindp8 than the WT, as demonstrated by the large amount of
heparin fragments whose migration the mutants have impeded (Figure A). On the other
hand, heparin affinity of the C176S/C191S mutant was no different
compared to the WT. The linker mutants also significantly increased
the amount of DS dp8 fragments shifted compared to the WT, but the
C176S/C191S mutant did not show significant changes compared to the
WT. Both are in agreement with the ELISA results. It should be noted
that, because of DBPA’s weaker affinity for DS, twice as much
DBPA was required to shift a comparable amount of DS as heparin fragments.
Figure 4
GMSA of
heparin dp8 (A) and DS dp8 (B) in the presence of either
1 or 0.5 equiv of WT N40 DBPA and N40Δ62–66, N40Δ62–71, N40Δ62–74, and N40 C176S/C191S mutants.
GMSA of
heparindp8 (A) and DS dp8 (B) in the presence of either
1 or 0.5 equiv of WT N40DBPA and N40Δ62–66, N40Δ62–71, N40Δ62–74, and N40 C176S/C191S mutants.We then characterized these interactions using solution NMR
titrations.
We used heparindp8 as the representative GAG ligand because our previous
NMR work has shown that DBPA binding to DS fragments fall within the
intermediate exchange regime on the NMR time scale, preventing accurate
extraction of KD values, and GMSA data
indicate that the relative heparin affinities reliably capture their
affinities for DS.[15,16] For the NMR studies, the mutants
were titrated with heparindp8, and large binding-induced chemical
shift perturbations of the pocket residues (T90, T140, and R169) were
measured and fitted to obtain the KD. Figure shows the chemical
shift changes of T140 in WT and mutant N40DBPA as well as the binding
curves derived from these data. Table summarizes the KDs of
linker truncated DBPAs. Shortening the linker decreased KD from several mM to ∼0.2 mM for mutants with linkers
shortened by 10 residues or more. On the other hand, KD for the disulfide bond mutant, C176S/C191S N40DBPA,
only decreased from several mM to ∼0.8 mM. This trend in KD values is qualitatively consistent with the
GMSA results. In total, these experiments demonstrate the effect of
removing the disulfide bond on N40DBPA’s GAG affinity is small.
Figure 5
15N-HSQC overlays of residue T140 of N40 DBPA variants
in the presence of increasing concentrations of heparin dp8. The lightest
contour represents the initial HSQC spectrum of N40 in the absence
of heparin dp8. Each subsequent contour represents the increasing
concentrations of heparin dp8:0.2, 0.4, 0.6, 0.8, 1.2, 1.6, and 2.0
mM. The concentration of N40 was 0.15 mM. Overlay of KD curves for T140 of each N40 variant is shown in the
bottom right panel.
Table 1
N40 Linker
Mutants Show Increased
Binding to Heparin Fragments (Heparin dp8 for NMR and Heparin dp10
for ITC)
NMR
ITC
N40 Variant
KD (μM)
KD (μM)
WT
>2 mM
>650
N40Δ62–66
495 ± 59
617 ± 55
N40Δ62–71
234 ± 11
153 ± 7
N40Δ62–74
200 ± 20
219 ± 6
C176S/C191S
751 ± 176
>650
15N-HSQC overlays of residue T140 of N40DBPA variants
in the presence of increasing concentrations of heparindp8. The lightest
contour represents the initial HSQC spectrum of N40 in the absence
of heparindp8. Each subsequent contour represents the increasing
concentrations of heparindp8:0.2, 0.4, 0.6, 0.8, 1.2, 1.6, and 2.0
mM. The concentration of N40 was 0.15 mM. Overlay of KD curves for T140 of each N40 variant is shown in the
bottom right panel.We also determined the global binding affinities
of the mutants
using isothermal titration calorimetry (ITC) to independently validate KD from the NMR experiments. The size of heparin
was increased by a disaccharide to obtain a higher change in enthalpy
so the KDs can be accurately measured. Figure and Table summarize the result of the
ITC experiments. The ITC data show that mutants with shortened linkers
were able to produce significantly higher changes in enthalpy than
WT or C176S/C191S N40DBPA. Trends of KD changes between the WT and mutants measured are also in complete
agreement with GMSA and NMR titration data. Namely, mutants with shortened
linkers showed significantly lower KDs
than the WT, and C176S/C191S N40DBPA showed negligible change compared
to the WT protein.
Figure 6
ITC titration curves of N40 DBPAs with heparin dp10. Values
of KDs extracted from these data are shown
in Table .
ITC titration curves of N40DBPAs with heparin dp10. Values
of KDs extracted from these data are shown
in Table .
Discussion
The results of this study
show the flexible linker of DBPA is a
critical negative regulator of GAG-affinity. This is consistent with
our hypothesis that the linker occludes the binding pocket and reduces
access of GAGs, thus reducing the protein’s affinity for GAGs
despite having a rich collection of basic amino acids in the pocket.
Shortening the linker removes the obstruction and increases the GAG
affinity. This is a novel result because conventional wisdom states
that GAG affinities of GAG-binding proteins are controlled mostly
by the number of basic amino acids in the binding site. However, residues
removed in this study are not part of the binding site and the number
of basic amino acids in the pocket was not altered. In addition, our
results show that the GAG affinity enhancement gained from shortening
the linker does not apply to all GAG types, and that linker truncation
enhanced heparin binding to a much greater extent than DS binding.These results explain much of the observed differences in GAG affinities
of DBPAs from different strains. N40DBPA,[10,11] whose basic pocket constitutes the only major GAG binding site,
has the weakest affinity because of lack of access to the basic pocket
by the ligand. B31 DBPA, on the other hand, possesses additional basic
residues clustered in its linker, allowing for increased electrostatic
interactions between the protein and GAGs through these more exposed
residues. PBrDBPA evolved an alternate strategy to overcome the barrier
of occluded GAG-binding site by having a helical linker, whose compact
shape allows the pocket to be much more exposed and accessible for
interactions with GAGs. Considering PBrDBPA shows higher affinity
for heparin-like GAGs than N40 or B31 DBPAs, these differences in
affinity may be a factor in determining tissue tropism during infection.
Knowing the mechanisms that regulate GAG affinities could therefore
allow more accurate prediction of how GAG–DBPA interactions
determine localization of Lyme disease.The fact that the linker
residues occlude the basic pocket does
not mean the basic residues in the pocket do not play a role in GAG
binding. Indeed, previous studies have shown that mutating these residues
to serine reduced GAG affinity.[12,14,15] These residues can contribute to GAG binding through at least two
mechanisms: first, because electrostatic interactions are long-range,
the presence of these residues in the vicinity may be sufficient to
attract GAGs without direct contact, the protein–GAG complex
can then be stabilized through formation of hydrogen bonds with polar
residues in the linker; second, the large size of most native GAG
chains means multivalent interactions between DBPA and GAGs will significantly
enhance affinity in vivo. It also should not be surprising that evolutionary
pressures have not managed to produce a DBPA with a more efficient
GAG-binding mechanism. Higher GAG affinity does not imply more efficient
colonization. Biological processes such as bacterial infection are
usually fine-tuned to achieve an optimal level of interactions to
allow adhesion to host without attenuating proper dissemination. Furthermore,
even though these proteins’ affinity for GAG is weakened, through
avidity effects, they may still produce sufficient adherence to prevent
the bacterium from being cleared from the host tissue. Other GAG-binding
adhesins may also be in place to compensate for DBPAs’ weaker
affinity, thus reducing the pressure on the bacterium to generate
a more efficient GAG adhesin.GAG-binding proteins constitute
an important class of proteins
that control critical biological phenomena such as leukocyte trafficking,
blood coagulation, and cancer cell metastasis.[22,23] Because of their importance, there has always been an interest in
understanding factors determining these proteins’ specificity
and affinity for GAGs. However, high resolution structural information
on these systems is scarce because of the dynamic nature of these
interactions and heterogeneity existing in the GAG ligands. Available
structural data show that GAG-binding sites in these proteins adopt
diverse conformations and have little sequence homology. Although
most of these sites are enriched in basic amino acids, the number
of basic amino acids in the binding site is not always a good predictor
of the binding affinity.[5] Our current work
presented here shows that GAG affinities can also be regulated by
linker domains functioning as flaps. As far as we know, DBPA is the
only reported example of a protein regulating GAG affinity using such
a mechanism. However, given the prevalence of unstructured loops in
GAG-binding proteins, more proteins with such a regulatory mechanism
maybe identified in the future.
Authors: Ann-Maree Catanzariti; Tatiana A Soboleva; David A Jans; Philip G Board; Rohan T Baker Journal: Protein Sci Date: 2004-05 Impact factor: 6.725
Authors: B T Farmer; K L Constantine; V Goldfarb; M S Friedrichs; M Wittekind; J Yanchunas; J G Robertson; L Mueller Journal: Nat Struct Biol Date: 1996-12
Authors: J M Leong; H Wang; L Magoun; J A Field; P E Morrissey; D Robbins; J B Tatro; J Coburn; N Parveen Journal: Infect Immun Date: 1998-03 Impact factor: 3.441
Authors: Dagmar Sandbäck Pikas; Eric L Brown; Sivashankarappa Gurusiddappa; Lawrence Y Lee; Yi Xu; Magnus Höök Journal: J Biol Chem Date: 2003-05-20 Impact factor: 5.157
Authors: Pavlina Vechtova; Jarmila Sterbova; Jan Sterba; Marie Vancova; Ryan O M Rego; Martin Selinger; Martin Strnad; Maryna Golovchenko; Nataliia Rudenko; Libor Grubhoffer Journal: Parasit Vectors Date: 2018-11-14 Impact factor: 3.876
Authors: Elaheh Movahed; David J Vance; Dylan Ehrbar; Greta Van Slyke; Jennifer Yates; Karen Kullas; Michael Rudolph; Nicholas J Mantis Journal: mSphere Date: 2022-07-25 Impact factor: 5.029